ClinicalTrials.gg

Program

balinatunfib

Also written as “SAR441566” and “Balinatunfib”.

Its studies are mostly in Arthritis, Rheumatoid · Colitis, Ulcerative · Psoriasis · Crohn Disease, led by Sanofi.

Furthest: phase 2, since Oct 4, 20239 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi90 open or runningphase 2since Oct 4, 2023Jul 7, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 7, 2022First study: phase 1 study in PsoriasisFirst studyNCT05453942 · 38 enrolled · Germany
  2. Apr 12, 2023Phase 1 study in Arthritis, RheumatoidNCT05844735 · 60 enrolled · United States
  3. May 5, 2023Phase 1 study in Arthritis, RheumatoidNCT05858788 · 10 enrolled · United States
  4. Oct 4, 20232 phase 2 studiesNCT06073119, NCT06073093
  5. Oct 10, 2024Phase 2 study in Crohn DiseaseNCT06637631 · 105 enrolled · United States, Argentina, Australia and more
  6. Mar 4, 2025Phase 2 study in Colitis, UlcerativeNCT06867094 · 170 enrolled · United States, Argentina, Australia and more
  7. Oct 27, 2025Phase 2 study in Colitis, UlcerativeNCT07222189 · 7 enrolled · United States, Argentina, Bulgaria and more
  8. Nov 26, 2025Phase 1 study in Cardiac RepolarizationNCT07272629 · 48 enrolled · United States
  9. Oct 13, 2026Phase 2 study terminatedStudy stoppedNCT06637631 · “Business decision.”
  10. Oct 21, 2026Phase 2 study terminatedStudy stoppedNCT06867094 · “Business decision”
  11. Oct 22, 2026Phase 2 study terminatedStudy stoppedNCT07222189 · “Business decision”

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07272629Cardiac Repolarization · United States1CompletedMay 28, 202648
NCT07222189Colitis, Ulcerative · United States, Argentina, Bulgaria and more2TerminatedSep 29, 20267
NCT06867094Colitis, Ulcerative · United States, Argentina, Australia and more2TerminatedAug 6, 2026170
NCT06637631Crohn Disease · United States, Argentina, Australia and more2TerminatedJul 30, 2026105
NCT06073119Psoriasis · United States, Argentina, Bulgaria and more2CompletedNov 13, 2024221
NCT06073093Arthritis, Rheumatoid · United States, Argentina, Brazil and more2CompletedJun 18, 2025264
NCT05858788Arthritis, Rheumatoid · United States1CompletedJul 17, 202310
NCT05844735Arthritis, Rheumatoid · United States1CompletedOct 15, 202360
NCT05453942Psoriasis · Germany1CompletedFeb 9, 202338

How it is read

Names in the registry

  • “SAR441566”, 7 entries
  • “balinatunfib”, 1 entry
  • “Balinatunfib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
balinatunfib (Sanofi): development program | ClinicalTrials.gg